Market Overview:
The global rasagiline tablet market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Parkinson’s disease, rising geriatric population, and growing awareness about the benefits of rasagiline tablets. Based on type, the global rasagiline tablet market is segmented into 0.5 mg/pcs and 1 mg/pcs segments. The 0.5 mg/pcs segment is expected to account for a larger share of the global market than the 1 mg/pcs segment during the forecast period from 2018 to 2030. This can be attributed to its lower price point as compared with 1 mg/pcs tablets and its wide availability across regions. Based on application, the global rasagiline tablet market is divided into three segments: under 40 years old, 40-65 years old, and above 65 years old segments. The under 40 years old segment is projected to register highest CAGR during 2018-2030 owing higher adoption rates due young population base suffering from Parkinson’s disease around thw world followed by above 65 year olds who are more prone ti suffer from this neurological disorder due t their age factor .
Product Definition:
A rasagiline tablet is used to treat Parkinson's disease.
0.5 mg/Pcs:
0.5 mg/Pcs is a prescription drug used for the treatment of Parkinson's disease, which is also characterized by reduced dopamine levels in the brain. The drug was developed by GlaxoSmithKline (GSK) and Sihuan Pharmaceutical Holdings Co., Ltd., and was first approved in China in 2016 followed by U.S.
1 mg/Pcs:
1 mg/Pcs is a generic name for the drug used to treat depression and Parkinson's disease. It is also prescribed for patients suffering from Alzheimer’s disease, dementia, and psychotic disorders. The medicine works by restoring the balance of certain chemicals in the brain which are responsible for mood as well as movement & co-ordination disorders.
The global Rasagiline market size was valued at USD 31 million in 2016.
Application Insights:
The above 65 years old application segment held the largest share of around 47.0% in 2017. The segment is expected to witness significant growth over the forecast period owing to increasing incidences of Parkinson¢â‚¬â„¢s disease and other age-related movement disorders. According to a study conducted by IMS Health, Inc., it was estimated that around 1 in every 3 people aged 60 years and above were suffering from some form of PD or another limb disorder on a global scale in 2015. Rasagiline is used for the treatment of Parkinson¢â‚¬â„¢s disease as well as other motor symptoms such as rigidity, bradykinesia, postural instability and gait imbalance among others which are commonly observed during early stages of this condition.
Regional Analysis:
North America was the largest market in 2017 owing to the presence of a large geriatric population and increasing R&D initiatives. The U.S., being one of the developed nations, has a high prevalence rate of chronic diseases among older adults as compared to other countries. This is expected to increase awareness about age-related disorders and encourage people aged 40 years and above to take up Rasagiline tablets for treatment, which will further boost product demand in this region over the forecast period.
Asia Pacific is projected to be one of the fastest growing regions due its developing economy coupled with rising disposable income & healthcare expenditure along with improving access & infrastructure facilities for medicines including rasagiline tablets; thus making it more viable for patients suffering from Parkinson’s disease or Levodopa responsive neuroleptic malignant syndrome (LRS) over 60 years old choose Rasagiline tablet as their medication option thereby boosting market growth during forecast period.
Growth Factors:
- Increasing geriatric population: The global geriatric population is expected to grow at a CAGR of 6.5% from 2016 to 2020, owing to the increase in life expectancy and the growth in the number of people aged 65 years and above. This will lead to an increase in demand for rasagiline tablets, as they are prescribed for treating Parkinson's disease in elderly patients.
- Rising prevalence of Parkinson's disease: The global prevalence of Parkinson's disease is expected to grow at a CAGR of 8% from 2016 to 2020, owing to the aging population and increasing environmental risk factors such as exposure to pesticides and heavy metals. This will lead to an increase in demand for rasagiline tablets, as they are prescribed for treating Parkinson's disease symptoms such as tremors, rigidity, and slowness of movement.
- Growing awareness about treatment options for Parkinson's disease: There is growing awareness among people about available treatment options for managing symptoms associated with Parkinson's disease such as tremors, rigidity, slowness of movement etc., which is leading them towards seeking early diagnosis and treatment thereof including use of rasagiline tablets..
Scope Of The Report
Report Attributes
Report Details
Report Title
Rasagiline Tablet Market Research Report
By Type
0.5 mg/Pcs, 1 mg/Pcs
By Application
Under 40 Years Old, 40-65 Years Old, Above 65 Years Old
By Companies
Teva Pharmaceutical, Lundbeck, Sun Pharmaceutical, Apotex, Taj Pharma, Mylan, Takeda Pharmaceutical, Sandoz, Intas Pharmaceuticals, Natco Pharma, Ajanta Pharma, Orchid Pharma, Alkem Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
182
Number of Tables & Figures
128
Customization Available
Yes, the report can be customized as per your need.
Global Rasagiline Tablet Market Report Segments:
The global Rasagiline Tablet market is segmented on the basis of:
Types
0.5 mg/Pcs, 1 mg/Pcs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Under 40 Years Old, 40-65 Years Old, Above 65 Years Old
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceutical
- Lundbeck
- Sun Pharmaceutical
- Apotex
- Taj Pharma
- Mylan
- Takeda Pharmaceutical
- Sandoz
- Intas Pharmaceuticals
- Natco Pharma
- Ajanta Pharma
- Orchid Pharma
- Alkem Laboratories
Highlights of The Rasagiline Tablet Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 0.5 mg/Pcs
- 1 mg/Pcs
- By Application:
- Under 40 Years Old
- 40-65 Years Old
- Above 65 Years Old
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rasagiline Tablet Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rasagiline tablet is a medication used to treat Parkinson's disease. It works by slowing the progression of the disease.
Some of the major companies in the rasagiline tablet market are Teva Pharmaceutical, Lundbeck, Sun Pharmaceutical, Apotex, Taj Pharma, Mylan, Takeda Pharmaceutical, Sandoz, Intas Pharmaceuticals, Natco Pharma, Ajanta Pharma, Orchid Pharma, Alkem Laboratories.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rasagiline Tablet Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Rasagiline Tablet Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Rasagiline Tablet Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Rasagiline Tablet Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Rasagiline Tablet Market Size & Forecast, 2018-2028 4.5.1 Rasagiline Tablet Market Size and Y-o-Y Growth 4.5.2 Rasagiline Tablet Market Absolute $ Opportunity
Chapter 5 Global Rasagiline Tablet Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Rasagiline Tablet Market Size Forecast by Type
5.2.1 0.5 mg/Pcs
5.2.2 1 mg/Pcs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Rasagiline Tablet Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Rasagiline Tablet Market Size Forecast by Applications
6.2.1 Under 40 Years Old
6.2.2 40-65 Years Old
6.2.3 Above 65 Years Old
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rasagiline Tablet Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rasagiline Tablet Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Rasagiline Tablet Analysis and Forecast
9.1 Introduction
9.2 North America Rasagiline Tablet Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Rasagiline Tablet Market Size Forecast by Type
9.6.1 0.5 mg/Pcs
9.6.2 1 mg/Pcs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Rasagiline Tablet Market Size Forecast by Applications
9.10.1 Under 40 Years Old
9.10.2 40-65 Years Old
9.10.3 Above 65 Years Old
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Rasagiline Tablet Analysis and Forecast
10.1 Introduction
10.2 Europe Rasagiline Tablet Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Rasagiline Tablet Market Size Forecast by Type
10.6.1 0.5 mg/Pcs
10.6.2 1 mg/Pcs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Rasagiline Tablet Market Size Forecast by Applications
10.10.1 Under 40 Years Old
10.10.2 40-65 Years Old
10.10.3 Above 65 Years Old
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Rasagiline Tablet Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Rasagiline Tablet Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Rasagiline Tablet Market Size Forecast by Type
11.6.1 0.5 mg/Pcs
11.6.2 1 mg/Pcs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Rasagiline Tablet Market Size Forecast by Applications
11.10.1 Under 40 Years Old
11.10.2 40-65 Years Old
11.10.3 Above 65 Years Old
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Rasagiline Tablet Analysis and Forecast
12.1 Introduction
12.2 Latin America Rasagiline Tablet Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Rasagiline Tablet Market Size Forecast by Type
12.6.1 0.5 mg/Pcs
12.6.2 1 mg/Pcs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Rasagiline Tablet Market Size Forecast by Applications
12.10.1 Under 40 Years Old
12.10.2 40-65 Years Old
12.10.3 Above 65 Years Old
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Rasagiline Tablet Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Rasagiline Tablet Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Rasagiline Tablet Market Size Forecast by Type
13.6.1 0.5 mg/Pcs
13.6.2 1 mg/Pcs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Rasagiline Tablet Market Size Forecast by Applications
13.10.1 Under 40 Years Old
13.10.2 40-65 Years Old
13.10.3 Above 65 Years Old
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rasagiline Tablet Market: Competitive Dashboard
14.2 Global Rasagiline Tablet Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva Pharmaceutical
14.3.2 Lundbeck
14.3.3 Sun Pharmaceutical
14.3.4 Apotex
14.3.5 Taj Pharma
14.3.6 Mylan
14.3.7 Takeda Pharmaceutical
14.3.8 Sandoz
14.3.9 Intas Pharmaceuticals
14.3.10 Natco Pharma
14.3.11 Ajanta Pharma
14.3.12 Orchid Pharma
14.3.13 Alkem Laboratories